PCM
AIMT

Princeton Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Princeton Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,000
Closed -$27K – 297
2018
Q2 		$27K Buy
+1,000
New +$30.6K 0.01% 212

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Princeton Capital Management's AIMT Position: Q3 2018 in Review

Princeton Capital Management sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 1,000 shares — an estimated $27K sold.

Princeton Capital Management first reported a position in AIMT in Q2 2018 and held it in 1 quarter. The position peaked at $27K in Q2 2018. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Princeton Capital Management reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Princeton Capital Management sold 1,000 Aimmune Therapeutics shares in Q3 2018, an estimated $27K.
  • Princeton Capital Management first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 1 quarter.
  • Princeton Capital Management's Aimmune Therapeutics position peaked at $27K in Q2 2018.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Princeton Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.